CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells by unknown
Zhang et al. Journal of Experimental & Clinical Cancer Research 2014, 33:93
http://www.jeccr.com/content/33/1/93RESEARCH Open AccessCK2α, over-expressed in human malignant pleural
mesothelioma, regulates the Hedgehog signaling
pathway in mesothelioma cells
Shulin Zhang1,2†, Yi-Lin Yang2†, Yucheng Wang3, Bin You2,4, Yuyuan Dai2, Geraldine Chan2, David Hsieh2,
Il-Jin Kim2, Li Tai Fang2, Alfred Au5, Hubert J Stoppler6, Zhidong Xu2, David M Jablons2 and Liang You2*Abstract
Background: The Hedgehog (Hh) signaling pathway has been implicated in stem cell maintenance and its
activation is aberrant in several types of cancer including mesothelioma. Protein kinase CK2 affects several cell
signaling pathways through the mechanism of phosphorylation.
Methods: Protein and mRNA levels of CK2α and Gli1 were tested by quantitative RT-PCR and immunohistochemistry
staining in mesothelioma samples and cell lines. Down-regulated Gli1 expression and transcriptional activity were
demonstrated by RT-PCR, Western blot and luciferase reporter assay.
Results: In this study, we show that CK2α is over-expressed and a positive regulator of Hegdehog/Gli1 signaling
in human malignant pleural mesothelioma. First of all, we found that the mRNA levels of CK2α and Gli1 were
broadly elevated and correlated (n = 52, r = 0.401, P < 0.05), compared with LP9 (a normal mesothelial cell line).
We then investigated their expression at the protein level, and found that all the 7 mesothelioma cell lines
tested showed positive staining in CK2α and Gli1 immunohistochemistry. Correlation analysis by Pearson test for
CK2α and Gli1 expression in the 75 mesothelioma tumors and the 7 mesothelioma cell lines showed that the
two protein expression was significantly correlated (n = 82, r = 0.554, P < 0.01). Furthermore, we demonstrated
that Gli1 expression and transcriptional activity were down-regulated after CK2α was silenced in two mesothelioma
cell lines (H28 and H2052). CK2α siRNA also down-regulated the expression of Hh target genes in these cell lines.
Moreover, treatment with a small-molecule CK2α inhibitor CX-4945 led to dose-dependent inhibition of Gli1
expression and transcriptional activity. Conversely, forced over-expression of CK2α resulted in an increase in
Gli1 transcriptional activity in H28 cells.
Conclusions: Thus, we report for the first time that over-expressed CK2α positively regulate Hh/Gli1 signaling
in human mesothelioma.
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Protein kinase CK2 (formerly known as casein kinase II) is a
highly conserved serine/threonine kinase that phosphory-
lates more than 300 proteins [1]. CK2 has a heterotetrameric
structure consisting of two catalytic subunits (42-kDa α or
38-kDa α’) and the regulatory subunit (28-kDa β), forming* Correspondence: Liang.You@ucsfmedctr.org
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functional protein kinase [2], that has been shown to be
involved in nearly every aspect of cell proliferation and
survival [3-5]. The level of CK2α expression is tightly
regulated in normal cells [6], and increased CK2α level and
activity has been consistently observed in a variety of human
cancers [7-9]. For instance, a high level and/or nuclear
localization of CK2α is a marker of poor prognosis for
patients with acute myeloid leukemia, chronic lymphocytic
leukemia, prostate cancer and gastric cancer [10-13]. In
addition, stable knockdown CK2α has recently been shownLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cinoma [14]. Studies also revealed that CK2 affects several
cell signaling pathways, including PI3K, NFkB and Wnt
[6,15,16].
The Hedgehog (Hh) family of secreted proteins, which
consists of Sonic, Indian and Desert Hedgehog, plays
important roles in mammalian development and in stem
cell maintenance [17,18]. The Hh pathway is activated at
the cell surface by the Hh ligand binding to its receptor
Patched (Ptc), resulting in derepression of the effector
protein, a G-protein-coupled receptor, Smoothened (Smo)
[19]. Ultimately, Smo activates the Gli family of transcrip-
tion factors and target genes. There are three Gli proteins
in humans: Gli1 activates Hh target genes, Gli2 acts both
as activator and repressor of Hh target genes, while Gli3
acts as a repressor of Hh target genes [20,21]. Deregu-
lation of Hh/Gli signaling is implicated as an initiating
or maintaining factor in the progression of various
cancers, including basal cell carcinomas, medulloblas-
tomas, leukemia, gastrointestinal, lung, ovarian, breast
and prostate cancers [20,22]. For instance, the Gli1
gene is amplified in human glioma and activated in basal
cell carcinoma [23-25]. Transgenic over-expression of
Gli1 in mice leads to the development of basal cell car-
cinoma [26]. Hedgehog pathway inhibitor GDC-0449
is an FDA-approved drug for treatment of metastatic
basal cell carcinoma.
Malignant pleural mesothelioma (mesothelioma) is an
aggressive cancer with poor prognosis that originates
mostly from the pleura of the lung. Mesothelioma is
associated with occupational exposure to asbestos [27].
It has been suggested that mesotheliomas contain cancer
stem cells and their stem cell characteristics are thought
to confer therapy-resistance [28]. Activated stem cell sig-
naling in patients has already been suggested in meso-
thelioma. For instance, cells staining positive for nuclear
beta-catenin, a marker for Wnt signaling activation, have
been reported in a few studies [29,30].
Recently, Hh/Gli1 signaling was reported to be aber-
rantly activated in human mesothelioma [31,32]. To date,
there is no evidence for the status of CK2 in mesothelioma.
The relationship between CK2 and Hh/Gli1 signaling in
mesothelioma is unknown. We therefore sought to detect
CK2α and Gli1 expression in primary mesothelioma tissues
and cell lines, and to analyze their relationship.
Methods
Cell culture and small molecule treatment
Nine human mesothelioma cell lines (H28, H290, H2052,
211H, H2452, MS-1, H226, REN and H513) and a normal
pleura cell line (LP9) were obtained from American Type
Culture Collections (Manassas, VA). Cells were routinely
maintained in RPMI-1640 supplemented with 10% heat-
inactivated fetal bovine serum, penicillin (100 μg/ml) andstreptomycin (100 μg/ml). All cells were routinely culti-
vated at 37°C in a humid incubator with 5% CO2. Treat-
ment with CX-4945 (Synkinase, San Diego, CA) and TBB
(Sigma, St. Louis, MO) dissolved in DMSO was adminis-
tered at several dosages. Cells were grown in medium for
48 hours after treatment. Cell proliferation in vitro was
assessed using a CellTiter-Glo Luminescent cell viability
assay (Promega Corporation, Madison, WI), according to
the manufacturer’s protocol [33].
Tissue samples and immunohistochemistry (IHC)
Fresh mesothelioma tissues were obtained from patients
who were undergoing surgical resection of the primary
tumor. All human tissue samples were obtained and ana-
lyzed in accordance with procedures approved by the insti-
tutional review board of the University of California, San
Francisco (IRB H8714-22 942–01). The tissue microarray
sections were immunostained as previously described [33].
Anti-CK2α antibody was from Millipore (Billerica, MA).
Anti-Gli1 antibody was from Cell Signaling (Beverly, MA).
The following scoring system was used: −, no stain; +, weak
staining (10% or above stained cellularity considered as
positive); ++, moderate staining (30% or above stained
cellularity considered as positive); +++, strong staining
(50% or above stained cellularity considered as posi-
tive). All scoring was done under low power objective
lens (10×) with a Zeiss Axioscop 2 microscope (Carl
Zeiss Inc, Germany). Images were taken under 10x or
40x objective lens.
SiRNA and plasmid DNA transfection
CK2α siRNA (ON-TARGET plus SMARTpool) and control
siRNA were purchased from Thermo Scientific (Waltham,
MA). Cells were seeded in a 6-well plate as 105 cells/well
one day before transfection, with a target of 30-50%
confluency at the time of transfection. Cells were trans-
fected with 50 nmol/L of siRNA using Lipofectamine
RNAiMAX (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. Adequate inhibition of the siRNA-
mediated knockdown was confirmed by Western blot. The
pcDNA3.1-CK2α or control pcDNA3.1-LacZ plasmid vec-
tors were then transfected into the H28 cells (0.5 μg/ml in
24-well plate) using Lipofectamine 2000 transfection
reagent (Invitrogen), according to the manufacturer’s
protocol. Cells were harvested for RT-PCR and Western
blot or used in reporter assays at 48 hours post-transfection.
RNA isolation, cDNA synthesis and semi-quantitative
RT-PCR
RNA was isolated using the RNeasy Mini kit (Qiagen,
Valencia, CA). Human Lung Total RNA was purchased
from Applied Biosystems (Foster City, CA). Five-hundred
ng of total RNA was converted into 20 μl cDNA using
iScript cDNA Synthesis Kits (Bio-Rad, Hercules, CA,)
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bands were visualized under UV light and photographed.
Quantitative RT-PCR
A total of 2 μl of the reverse transcription reaction were
used as template for real-time detection using TaqMan
Technology on an Applied Biosystems 7000 sequence
detection system (Applied Biosystems). Gene expression
was quantified for the tested genes and endogenous control
gene b-glucuronidase (GUSB) using commercially available
primer and probe sequences (Applied Biosystems). Relative
mRNA level was calculated by normalizing the gene
expression levels of tested genes to that of the control
GUSB gene.
Western blot analysis
Whole protein was extracted by M-PER Mammalian
Protein Extraction Reagent (Thermo) from cell lines added
with Phosphatase Inhibitor Cocktail Set II (Calbiochem,
San Diego, CA) and Complete Protease Inhibitor Cocktails
(Roche, Lewes, UK) according to manufacturers’ protocols.
The proteins were separated on 4–15% gradient SDS–
polyacrylamide gels and transferred to Immobilon-P
membranes (Millipore, Bellerica, MA). The following
primary antibodies were used: anti-CK2α (Millipore),
anti-Gli1 (Cell Signaling), and anti-GAPDH (Trevigen,Figure 1 mRNA level and correlation of CK2α and Gli1. (A) CK2α in
lines. (C) Gli1 in primary mesothelioma samples. (D) Gli1 in mesothelio
(r = 0.401, P < 0.05).Gaithersburg, MD). After being incubated with appropri-
ate secondary antibodies, the antigen-antibody complexes
were detected by using an ECL blotting analysis system
(Amersham Pharmacia Biotech, Piscataway, NJ). Digital
images were prepared using Adobe Photoshop CS3.
Luciferase reporter assays
To measure Gli-mediated Hh transcriptional activity,
the luciferase reporter constructs, 8× wild-type Gli
binding site (8× Gli wt Luc) or 8× mutant Gli binding
site (8× Gli mut Luc) plasmids [34] and a human Gli1
expression vector (pcDNA3.1-Gli1) were co-transfected
into H28 cells in 24-well plates. The Renilla luciferase
pRL-TK plasmid (Promega, Madison, WI), whose expres-
sion is driven by the housekeeping thymidine kinase gene
promoter, was co-transfected to normalize for transfection
efficiency. All transfection experiments were performed
using the Lipofectamine2000 (Invitrogen) in accordance
with the manufacturer’s instructions. After 24 h cells were
lysed and luciferase assays were performed as described
previously [35]. Results are expressed as fold induction,
which is the ratio of luciferase activity induced in
Gli-transfected cells relative to basal luciferase activity
in control transfected H28 cells. All experiments were
performed in triplicate; means and standard errors were
calculated using Student’s t-test.primary mesothelioma samples. (B) CK2α in mesothelioma cell
ma cell lines. (E) Correlation between CK2α and Gli1 mRNA levels
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Data were expressed as mean ± standard deviation (SD)
from three independent experiments. All of the statistical
analyses were performed using SPSS 13.0 for Windows
software system (SPSS Inc, Chicago, IL). Student’s t-test
was used to compare the differences among groups. Pear-
son product correlation tests (in the form of a correlation
matrix) were used to analyze the mRNA and protein level
of CK2α and Gli1. A significant difference was de-
clared if the P value from a two-tailed test was less
than 0.05 (* P <0.05, ** P <0.01).Results
Quantitative RT-PCR of CK2α and Gli1
Quantitative RT-PCR was used to examine the mRNA
level of CK2α and Gli1 in 44 primary mesothelioma sam-
ples and 8 mesothelioma cell lines (H28, H290, H2052,
211H, H2452, MS-1, H226 and H513). As shown in
Figure 1A, 97.7% (43/44) primary samples showed dra-
matically elevated CK2α mRNA level, compared with a
normal pleura cell line LP9. In analysis of the cell lines,
87.5% (7/8) showed significantly elevated CK2α expres-
sion mRNA level, compared with LP9 (Figure 1B). All ofFigure 2 IHC of CK2α and Gli1 in primary mesothelioma samples and
pleura sample; (III– VII) mesothelioma samples. (B) CK2α in mesothelioma c
Lung cancer cell line A427 (positive control), +++. (C) Gli1 in primary meso
samples. (D) Gli1 in mesothelioma cell lines. (I, II) 211H, ++; (III, IV) MS-1, +
control), +++. Images were taken under 10x or 40x objective lens.the primary samples and the cell lines showed elevated
Gli1 mRNA level, compared with LP9 (Figure 1C-D).Immunohistochemistry of CK2α and Gli1 in mesothelioma
Both CK2α and Gli1 genes are over-expressed in a var-
iety of cancers [36,37]. However, whether CK2α is over-
expressed in mesothelioma is unknown. First, by using
the immunohistochemistry (IHC) staining, we detected
the protein level of CK2α and Gli1 in 75 primary meso-
thelioma samples and 7 cell lines (H28, H290, 211H,
H2452, MS-1, H226 and REN) of the tissue microarray
sections. The positive or negative results of CK2α and
Gli1 staining in these sections are shown in Figure 2 and
Tables 1, 2 and 3. Lung cancer cell line A427 with strong
positive (+++) staining of CK2α and Gli1 was used as a
positive control. In the primary mesothelioma samples
(Figure 2A, C and Tables 1 and 2), the overall positive
ratios of CK2α and Gli1 were both 93.3% (70/75). The
moderate and strong positive (++/+++) ratio was 69.3%
(52/75) in CK2α staining and 50.6% (38/75) in Gli1
staining. The strong positive (+++) ratio was high (40%)
in CK2α staining. The strong positive ratio of Gli1 stain-
ing was lower (17.3%) than that of CK2α staining. Incell lines. (A) CK2α in primary mesothelioma samples. (I, II) normal
ell lines. (I, II) 211H, ++; (III, IV) MS-1, +++; (V, VI) H2452, +++; (VII, VII)
thelioma samples. (I, II) normal pleura sample; (III– VII) mesothelioma
++; (V, VI) H2452, +++; (VII, VII) Lung cancer cell line A427 (positive
Table 1 Immunohistochemistry findings from human mesothelioma samples
Sample no. IHC of anti-CK2α IHC of anti-Gli1 Sample no IHC of anti-CK2α IHC of anti-Gli1
T01 - + T45 + +
T02 + ++ T46 +++ +++
T03 ++ + T47 +++ +
T04 + + T48 + +
T05 + + T49 ++ ++
T06 ++ ++ T50 +++ ++
T07 +++ ++ T51 +++ ++
T08 ++ + T52 +++ -
T09 + ++ T53 +++ ++
T10 ++ ++ T54 ++ +
T11 +++ +++ T55 +++ +
T12 +++ ++ T56 ++ +
T13 +++ + T57 ++ ++
T14 + + T58 +++ +++
T15 +++ ++ T59 ++ +++
T16 ++ ++ T60 - ++
T17 ++ + T61 + +
T18 + + T62 ++ ++
T19 ++ + T63 +++ +
T20 +++ +++ T64 +++ ++
T21 +++ +++ T65 ++ +++
T22 - - T66 ++ +
T23 +++ ++ T67 +++ +++
T24 + +++ T68 +++ +++
T25 +++ ++ T69 + +
T26 +++ +++ T70 + +
T27 ++ ++ T71 +++ +++
T28 +++ + T72 +++ +
T29 +++ ++ T73 +++ +
T30 ++ + T74 - -
T31 +++ ++ T75 + ++
T32 ++ + N1 - -
T33 + - N2 + +
T34 + + N3 + -
T35 + + N4 - -
T36 + + N5 - -
T37 ++ + N6 - -
T38 - - H226 + ++
T39 +++ ++ REN + ++
T40 +++ ++ H290 +++ +++
T41 ++ + 211H ++ ++
T42 ++ ++ H2452 +++ +++
T43 + +++ H28 ++ +
T44 ++ + MS-1 +++ +++
N = normal tissue; T = tumour tissue; IHC = immunohistochemistry; − = no stain; + = weak stain; ++ =moderate stain; +++ = strong stain.
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Table 2 Positive and negative number and ratio of CK2α and Gli1 in 75 primary mesothelioma samples
− Number (ratio) + Number (ratio) ++ Number (ratio) +++Number (ratio) Total (ratio)
CK2α 5 (6.67%) 18 (24.0%) 22 (29.3%) 30 (40.0%) 75 (100%)
Gli1 5 (6.67%) 32 (42.7%) 25 (33.3%) 13 (17.3%) 75 (100%)
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staining was negative (−) or weak (+) at the cell mem-
brane or in the region of cytoplasm near the mem-
brane (Figure 2A, C and Tables 1 and 3). In all the 7
cell lines tested, both CK2α and Gli1 showed positive
staining (Figure 2B, D and Table 1). For CK2α staining,
H290, H2452 and MS-1 were strong positive (+++),
while REN and H226 were weaker (+). For Gli1 stain-
ing, H290, H2452 and MS-1 were strong positive (+++),
while H28 was weaker (+). These results suggest an aber-
rant over-expression of CK2 and Gli1 in mesothelioma.
Correlation between CK2α and Gli1
To analyze the relationship between CK2α and Gli1 in
mesothelioma, we performed a Pearson product correl-
ation test on CK2α and Gli1 staining in the 75 primary
samples and the 7 cell lines. CK2α and Gli1 were mildly
correlated at the protein level (n = 82, r = 0.554, P < 0.01,
Table 4). We then investigated their relationship at
the mRNA level, and found that CK2α and Gli1 were
also broadly elevated and correlated (n = 52, r = 0.401,
P < 0.05, Figure 1E and Table 4) at the mRNA level.
Down-regulation of Hh/Gli1 signaling by CK2α
knockdown
To investigate whether CK2 has an effect on the Hh
pathway, we silenced CK2α expression for 48 h using
CK2α siRNA in H28 and H2052 cell lines. It has been
previously shown that 48 h of CK2α siRNA treatment is
efficient to knockdown CK2α protein expression in the
treated cells [38-41]. The efficiency of RNA interference
was monitored by semi-quantitative RT-PCR and Western
blot (Figure 3A and B). The corresponding mRNA and
protein levels of CK2α in H28 and H2052 cell lines de-
creased dramatically (Figure 3A and B, upper lane). Ex-
pression of Gli11 was inhibited after CK2α knockdown
in the two cell lines (Figure 3A and B, middle lane).
To confirm whether CK2α positively regulates Hh/Gli1
signaling, we performed a luciferase reporter assay to de-
tect the transcriptional activity of the pathway. SilencingTable 3 Positive and negative number of CK2α and Gli1
in normal pleura samples
− Number + Number ++ Number +++Number Total
CK2α 4 2 0 0 6
Gli1 5 1 0 0 6of CK2α in H28 cells resulted in a significant decrease
(48% at 50 μM, P < 0.01, Figure 3C) in the Gli reporter
activity, compared with the non-targeting siRNA (control).
To study the effects of CK2α knockdown on Hh/Gli1
signaling, quantitative RT-PCR was performed to com-
pare the levels of Gli1 and Ptc1 mRNA between wild-
type and CK2α knockdown cell lines. The mRNA level
of the two Hh target genes decreased significantly (P < 0.01,
Figure 3D) after CK2α knockdown. In normal mesothe-
lial LP9 cells, decrease in mRNA level of the two Hh
target genes was also detected using quantitative RT-
PCR (Additional file 1: Figure S1A). These results sug-
gest a depressed transcriptional activity of Hh/Gli1
signaling after CK2α knockdown.Down-regulation of Gli1 expression and transcriptional
activity by CK2α inhibitor
To extend our findings to clinical applications, we used a
small-molecule CX-4945 (5-(3-chlorophenylamino)benzo
[c][2,6]naphthyridine-8-carboxylic acid), a first-in-class,
selective, oral inhibitor of CK2α under investigation in
Phase 1 clinical trials [42]. Cells were treated with multiple
concentrations of CX-4945 (0.01, 0.03, 0.1, 0.3, 1, 3, 10
and 30 μM), or with the vehicle DMSO for 72 hours. The
cell proliferation assay demonstrated that treatments with
CX-4945 led to cell growth inhibition in a dose-dependent
manner, both in H28 and H2052 cell lines (IC50 values
were 7.2 μM in H28 and 2.0 μM in H2052, respectively,
Figure 4A). Normal mesothelial LP9 cells also showed a
dose-dependent inhibition on cell growth by CX-4945
treatment (IC50 values is 3.3 μM, Additional file 1:
Figure S1B). After treatment with CX-4945, Gli1 ex-
pression decreased noticeably at the dosage level of
3 μM in H2052 or 10 μM in H28, and decreased to
minimal at 10 μM in H2052 (Figure 4C). We further
demonstrated that treatment with CX-4945 led to a dose-
dependent decrease in Gli reporter activity in the H28 cells.
The decrease was 47% (P < 0.05) in the presence of 3 μM
CX-4945 or 70% (P < 0.01) in the presence of 10 μM CX-
4945 (Figure 4B). TBB (4,5,6,7-tetrabromobenzotriazole),Table 4 Correlation analysis of CK2α and Gli1 in
mesothelioma
N r P
mRNA 52 0.401 0.018
Protein 82 0.554 0.000
Figure 3 Down-regulation of Gli1 expression and transcriptional activity after CK2α knockdown in mesothelioma cell lines. (A) Gli1 mRNA
levels after treatment with CK2α siRNA. (B) Gli1 protein levels after treatment with CK2α siRNA. (C) The transcriptional activity of Gli1 after
treatment with CK2α siRNA in H28. Silencing of CK2α resulted in a significant decrease (more than 48% at 50 μM siRNA) of the transcriptional
activity. (D) Down-regulation of two target genes of the Hh pathway (Gli1 and Ptc1), detected by quantitative RT- PCR.
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positive control. 10 μM TBB led to an 80% decrease of
Gli1 transcriptional activity.
Transcriptional activation of Gli1 by forced over-
expression of CK2α
To confirm whether CK2 positively affects the transcrip-
tional activity of Gli1, we transfected H28 cells with either
a pcDNA3.1-CK2α or control pcDNA3.1-LacZ plasmid.
As expected, CK2α over-expression, detected by Western
blot (Figure 5A), was attributed to the activation of Gli1 in
H28 cells. The reporter assay also showed a significant
(>10-fold, P < 0.01) increase of Gli1 transcriptional activity
(Figure 5B). These findings suggest that forced over-expression of CK2α leads to a transcriptional activa-
tion of Gli1.
Discussion
Our results suggest that CK2α is over-expressed and
positively regulates Hh/Gli1 signaling in human malig-
nant pleura mesothelioma. This is supported by several
lines of evidence. First, broadly aberrant over-expression
of CK2 was demonstrated in most of the primary meso-
thelioma samples and cell lines we tested. Second, we
found a statistically mild correlation between CK2 and
Gli1 expression both at the mRNA and protein levels.
Third, in experimental studies of mesothelioma cell lines,
CK2α inhibition by siRNA or small-molecular inhibitor
Figure 4 Down-regulation of Gli1 expression and transcriptional activity after treatment with CX-4945. (A) Cell proliferation assay after
treatment with CX-4945. (B) Dose-dependent decrease in Gli reporter activity in H28. The decrease was 47% in the presence of 3 μM CX-4945 or
70% in the presence of 10 μM CX-4945. TBB was used as a positive control. (C) Dose-dependent decrease of Gli1 mRNA after treatment with
CX-4945. Gli1 expression decreased noticeably at the dosage levels of 3 μM in H2052 or 10 μM in H28, and decreased to minimal at 10 μM
in H2052.
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transcriptional activity. Finally, forced over-expression
of CK2α led to Gli1 transcriptional activation.
To date, there is no evidence for the expression status
of CK2 in mesothelioma, although CK2 reportedly
affects cell growth in several types of tumor. Our study
shows the broad over-expression of CK2α for the first
time. Our findings suggest that CK2 may play an
important role in mesothelioma pathogenesis and is a
potential biomarker and therapeutic target for patients
with mesothelioma. Further studies are warranted to
show evidence for patients who may potentially benefit
from CK2 inhibitors. CK2 inhibitors have not been ex-
tensively developed as therapeutic agents, partly because
the ATP-binding pocket of CK2 is not as druggable as
some other protein kinases [44-46]. To date, only onesmall-molecule CK2 inhibitor has been entered to clinical
trials as a potential anticancer drug [47]. CX-4945, a
highly selective CK2 small molecule inhibitor, is a promis-
ing first-in-class oral therapeutic agent that targets mul-
tiple human cancers. CX-4945 shows a favorable safety
profile in Phase I clinical trials [48]. In addition, CIGB-300
(a synthetic peptide-based drug targeting the CK2 phos-
phoaceptor domain) has proved to be safe and of clinical
benefit in Phase I cervical cancer trials [49].
Our study also demonstrates that Gli1 is over-expressed
in mesothelioma, indicating the presence of an active Hh
pathway. In several samples, the Gli1 mRNA level was
more than 1000-fold greater than that in the normal
pleura cell line LP9. This is consistent with findings from
the recent study that first reported the role of aberrant
Hh/Gli1 signaling in human mesothelioma [31]. The
Figure 5 Up-regulation of Gli1 transcriptional activity in forced over-expressed CK2α H28 cells. (A) Over-expression of CK2α detected by
Western blot. (B) Gli1 reporter assay. A significant (>10-fold) increase of the Gli1 transcriptional activity was shown in forced over-expressed CK2α
H28 cells.
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was recently analyzed using qRT-PCR, and SHH gene
expression was only detected in tumor tissue but not
in non-tumor pleural samples [31]. Moreover, in situ
hybridization analysis of mesothelioma tumors showed
similar results that the expression of SHH and DHH was
mostly associated with the tumor cells [31]. Together,
these results suggested that the Hh pathway expression on
mesothelioma cells is mostly from autocrine expression of
its ligands.
The Hh pathway plays key roles in maintaining cancer
stem cells, and an antagonist of hedgehog inhibits tumor
growth, indicating a new therapeutic approach on meso-
thelioma. However the druggable targets in the Hh path-
way are very limited; to date, only one Hedgehog inhibitor
GDC-0449 is approved by FDA for treatment of meta-
static basal cell carcinoma. Recently, we have shown that
CK2α regulates Hh/Gli1 signaling in human lung cancer,
and silencing of CK2α promotes Gli1 degradation in a
time-course experiment [39]. CK2α promotes Hh/Gli1
signaling by, at least in part, increasing Gli1 protein stabil-
ity [39]. Another study showed that silencing CK2α inhib-
ited the expressions of Gli1 and Patched homolog 1
(PTCH1) in hepatocellular carcinoma, resulting in the in-
activation of Hh signaling pathway [14]. The relationship
between CK2 and Hh/Gli1 signaling in other types of
cancer, including mesothelioma is still unknown.
In this study, correlated IHC staining of CK2α and
Gli1 in mesothelioma was demonstrated. For example,
32 of 38 (84.2%) of moderate and strong positive (++/+++)
staining of Gli1 existed in the 52 samples with moderate
and strong positive (++/+++) staining of CK2α. Nine of
thirteen (69.2%) of strong positive (+++) staining of Gli1
exited in the 30 samples with strong positive (+++) staining
of CK2α. We also analyzed CK2β expression in human
mesothelioma tumors using IHC. The CK2β staining was
compared with CK2α and Gli1 expression in the same
tumor samples (n = 61) (Additional file 1: Table S1). Asso-
ciation of CK2α and Gli1 expression in the tumors was
identified (Additional file 1: Table S2, p < 0.05, chi-square).
Association of CK2α and CK2β expression in the tumors
was shown (Additional file 1: Table S3, p < 0.05, chi-
square). However, association of CK2β and Gli1 expression
in the tumors was not statistically significant (Additional
file 1: Table S4, p > 0.05, chi-square). Taken together, our
results suggested that Gli1 expression is associated with
CK2α expression, but not CK2β expression, in the meso-
thelioma tumors. Furthermore, in the experimental studies
of mesothelioma cell lines, CK2α was suggested to posi-
tively regulate Hh/Gli1 signaling. Our study also suggests
that CK2 is an additional target for the inhibition of
Hh/Gli1 signaling in mesothelioma. Thus, CK2 inhibi-
tors such as CX-4945 may be potentially beneficial for
clinical treatment of patients with mesothelioma.Conclusions
In summary, we report that CK2 is over-expressed and
positively regulates Hh/Gli1 signaling in mesothelioma.
However, the precise mechanism needs to be elucidated.
Given the emerging importance of protein kinase CK2
and Hh/Gli1 signaling in tumor initiation and progres-
sion, our findings provide important new evidence for
the potential benefits of CK2 inhibitors.Additional file
Additional file 1: Table S1. Comparison of IHC analysis of CK2α, CK2β,
Gli1 expression in mesothelioma tumors. Effects of CK2α inhibition or
silencing in normal mesothelial LP9 cells. Table S2. Association analysis of
CK2α and Gli1 expression in mesothelioma tumors (p<0.05, Chi-square).
Table S3. Association analysis of CK2α and CK2_ expression in mesothelioma
tumors (p<0.05, Chi-square). Table S4. Association analysis of CK2_ and Gli1
expression in mesothelioma tumors (p>0.05, Chi-square). Figure S1.
(A) Down-regulation of two target genes of the Hh pathway (Gli1 and
Ptch1) in LP9 cells, detected by quantitative RT- PCR, after CK2α siRNA
treatment. (B) Cell proliferation assay after treatment with CX-4945.
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